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Abstract 
GEOGRAPHIC DISTRIBUTION OF THE RADIATION ONCOLOGY WORKFORCE: 
IMPLICATIONS ON PROSTATE CANCER. 
Sanjay Aneja and James B. Yu, Department of Therapeutic Radiology, Yale School of 
Medicine, New Haven, CT 
Previous analyses of the radiation oncology (RO) workforce have focused on gross numbers 
and not geographic distribution. We investigated trends in the geographic distribution of the 
radiation oncology workforce across the United States. Additionally, we assessed the impact 
of geographic variations in the RO workforce on prostate cancer management and outcomes. 
We hypothesized that geographic variations in the workforce would be associated with 
prostate cancer management and prostate-cancer mortality.   
We used the Area Resource File to calculate and map the ratio of radiation oncologists to the 
population aged 65 or older (ROR) within different health service areas (HSA) across the 
United States from 1995-2007. Multivariate regression models were built to test the 
association between ROR and socioeconomic variables (income, minority population, 
unemployment rate, population education). Using patient data from the Surveillance 
Epidemiology End Results Program (SEER) we built multivariate logistic regression models 
to test associations between variations in the RO workforce and patient decisions to observe, 
undergo a radical prostatectomy, or undergo radiation therapy. Using mortality data from the 
State Cancer Profiles dataset, we built multivariate linear regression to test the association 
between RO workforce and count-level age-adjusted prostate cancer mortality. 
Despite a 24% increase in the workforce from 1995 to 2007, there remained consistent 
geographic maldistribution of radiation oncologists, specifically affecting the rural HSAs. 
Regression analysis found higher ROR associated with  more educated (p=.001), affluent 
(p<.001) HSAs with lower unemployment rates (p<.001), and higher minority populations 
(p=.022). Of the 108,612 prostate cancer patients queried from the SEER dataset, patients 
with low-risk disease (p<.001) residing in HSAs with fewer radiation oncologists (p=.001-
.041), fewer urologists (p<.001),  and more primary care physicians (p<.001) were most 
likely to observed in lieu of curative treatment. Of the 91,643 patients who underwent some 
form of curative treatment, older, single (p<.001), African American patients (p<.001) with 
low-risk disease (p<.001) residing in HSAs with more radiation oncologists (p=.007-.001) 
and primary care physicians (p<.001) were more likely to receive radiation therapy. The 
presence of at least one radiation oncologist was associated with between 5.74% and 1.48% 
reduction in prostate cancer mortality (p=.001-.045) even when adjusting for county-level 
prostate cancer incidence.  
Despite a modest growth in the radiation oncology workforce, there exists persistent 
geographic maldistribution of radiation oncologists allocated along socioeconomic and racial 
lines. Regional variations in the RO workforce are associated with variations in the 
management of prostate cancer. The presence of at least one radiation oncologist is 
associated with a reduction in county-level prostate cancer mortality. There is a need for 
geographically aware policy in order to optimize the RO workforce and improve prostate 
cancer outcomes.   
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Introduction 
The Physician Workforce Crisis 
The physician workforce remains the cornerstone to delivering quality healthcare 
across the United States. Over the last 30 years, population growth has rapidly outpaced 
commensurate gains in the physician workforce threatening the sustainability of our 
country’s healthcare system.1 With recent passage of the Patient Protection and 
Affordable Care Act (ACA), the number of insured Americans is expected to increase by 
32 million widening the physician supply gap and increasing the clinical burden on the 
workforce.2 The Center for Workforce Studies projects the gap in the physician 
workforce to increase by 50% by the year 2050. Specifically, the shortage of specialists is 
expected to quadruple. 3 Because of this known association between access to care and 
healthcare quality, the ACA attempted to address the physician workforce issue through 
the establishment of the National Healthcare Workforce Commission, whose sole 
purpose is to monitor the supply and distribution of physicians. Along with the National 
Healthcare Workforce Commission, the ACA also established the Center for Medicare 
and Medicaid Innovation Center whose mission is to optimize the efficiency and quality 
of care provided by the current physician workforce.1  
Geography and the Physician Workforce 
Despite significant focus on the physician workforce problem, the geographic 
distribution of the workforce is often overlooked. Previous policy analyses of the 
physician workforce have primarily focused upon projecting future demand based on 
gross numbers of physicians.4,5 Geographic variations on the workforce have been 
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associated with disparities in health outcomes. Specifically within oncology, geographic 
access to care has known associations with cancer-related outcomes.  Increased urologist 
density has been shown to be associated with decreased prostate and kidney cancer 
mortality.6,7 Dermatologist density has been shown to be associated with reductions in 
melanoma mortality.8 Additionally increased density of primary care physicians has been 
associated with improved cancer specific mortality and all cause mortality.9 Moreover, 
geographic proximity to cancer specialists has been associated with variations in the 
management of breast cancer including surgical choice, and receipt of radiation 
therapy.10-13  Whether the current physician workforce is adequately and equitably 
distributed, to meet and optimize the growing demand for cancer care is an important 
area of ongoing study.6,14-16 
The Radiation Oncologist Workforce 
The workforce issue is not new to the field of radiation oncology. In 2002 the 
American Society for Radiology Oncology (ASTRO) Workforce Committee was the first 
to note shortages in the future of radiation oncology.17 More recently however, it has 
been projected that the demand for radiation therapy will increase 10 times faster than the 
supply for radiation oncologists.18 The radiation oncology workforce problem has likely 
exacerbated since ASTRO’s first report for at least three reasons. First, technological 
advancements in the field of radiation oncology have markedly increased the overall 
demand of radiation therapy to treat cancer despite recent declines in cancer 
incidence.18,19 Second, a supply gap has been created by modest increases in the number 
of training programs in the face of larger increases clinical demands.18,20 Third, 
technological advancements in the field that not only increased the quantity of treatment 
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but also physician planning time have potentially decreased the overall efficiency of the 
radiation oncologist workforce.18,21 
Similar to other specialties, previous analyses of the radiation oncology workforce 
have focused solely on radiation oncologist numbers and projecting the need for the 
future. Few studies, however, have addressed the geographic distribution of radiation 
oncologists. Though some disciplines may adapt to a lack of geographic distribution via 
the use of telemedicine or physician extenders, access to radiation oncology services is 
particularly dependent on geographic distribution for several reasons.  First, a clinical 
course of radiation therapy requires multiple daily trips for treatment, for up to eight or 
nine weeks in some cases.  Second, given the technical nature of radiation oncology, 
primary care physicians and physician extenders cannot as readily fill gaps in care caused 
by lack of radiation oncologists. Third, radiation therapy requires large and immobile 
equipment that cannot feasibly be transported or quickly erected.22 Descriptive analysis 
of the geographic distribution of the radiation oncology workforce is a necessary first 
step to help inform policy makers and clinicians in ways to best provide radiation therapy 
and multidisciplinary cancer care.  
Treatment of Prostate Cancer across the United States 
Prostate cancer is the most common non-cutaneous cancer among men in the 
Western world. With an estimated 200,000 diagnoses and 30,000 deaths each year, 
treatment of prostate cancer is of great medical and public significance.23 24 Despite its 
high occurrence rate, the relative 10-year survival rate following treatment of localized 
prostate cancer is 98%.23 Though evidence indicates that prostate cancer mortality has 
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been improving in recent years, the benefit from modern cancer treatment may not be 
uniform throughout the United States.25,26 Furthermore, as US population ages, the 
incidence of prostate cancer is expected to increase dramatically over the next 20 years. 
In addition to active surveillance, the two most common treatment interventions for 
patients with localized prostate cancer are prostatectomy and radiation therapy. Although 
no multi-institutional randomized control trials have compared the two modalities, 
retrospective studies from the Cleveland Clinic, Memorial Sloan Kettering Cancer Center, 
and the Joint Center for Radiation Therapy have all found similar biochemical failure 
rates among both modalities. 27-29 Moreover, despite the different side-effects profiles for 
each treatment option, recent evidence has found no significant differences in 15-year 
disease specific functional outcomes when comparing radical prostatectomy and external 
beam radiation therapy.30 
Several types of providers are involved in the diagnosis and treatment of prostate 
cancer.  Primary care providers and urologists are typically involved in initial diagnosis 
whereas urologists, medical oncologists, and radiation oncologists could all potentially be 
involved in the primary treatment of prostate cancer.  Patients are often influenced by 
counseling physicians when deciding their optimal treatment choice.31 This is particularly 
concerning given physicians opinions regarding both treatment modalities vary 
drastically based on specialty and geographic region.31 The influence the distribution of 
radiation oncologists, urologist and primary care providers on the management of 
prostate cancer remains unclear. 
Furthermore, the relative impact of the distribution of radiation oncologists, 
urologists, and primary care providers on prostate cancer mortality is unknown. As 
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radiation oncologists also serve as primary treatment providers for prostate cancer, the 
association between the availability of radiation oncologists and prostate cancer mortality 
merits exploration.  
It is likely that variation in the geographic distribution of radiation oncologists is 
related to the receipt of cancer treatment and outcomes, particularly for those patients 
who are not candidates for surgery.  Alternatively, patients who are surgical candidates, 
but refuse surgery, may choose radiation therapy as an alternative curative treatment if a 
radiation oncologist is geographically accessible.  External beam radiotherapy, the 
dominant form of radiation treatment in the US, typically requires multiple daily 
radiation treatments for 6-9 weeks, making the geographic distribution of radiation 
oncologists more important, particularly for patients with limited mobility and resources 
for travel. As it is known that travel time to the nearest cancer center varies significantly 
throughout the country, inequities in geographic access may be associated with variations 
in cancer mortality.32  
To investigate these issues, we studied trends in the geographic distribution of the 
radiation oncology workforce across the United States. Additionally, we studied the 
association between geographic variations in the radiation oncology workforce and 
regional prostate cancer management and mortality. We hypothesized that there existed 
geographic variations in the radiation oncology workforce that were associated with 
differences in the treatment choices of prostate cancer patients as well as prostate cancer 
mortality. 
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Project Aims 
1. To evaluation trends in the geographic distribution of the radiation oncology 
workforce from 1995 to 2007. 
2. To compare the trends in geographic distribution of the radiation oncology workforce 
to the primary care physician and total physician workforces from 1995 to 2007. 
3. To identify population and geographic factors associated with the distribution of the 
radiation oncologists in 2007.  
4. To evaluate associations between geographic variations in the radiation oncology 
workforce and patient prostate cancer treatment choice from 2004 to 2007 
5. To evaluate associations between geographic variations in the radiation oncology 
workforce and regional prostate-cancer mortality rates from 2003 to 2007. 
Hypothesis 
We expect to find significant geographic variations in the radiation oncology workforce 
that have persisted from 1995 to 2007. We also expect to find an association between 
regional variations in the radiation oncology workforce and the management of prostate 
cancer. Specifically, we expect regions with higher densities of radiation oncologists to 
have lower rates of surveillance and higher rates of radiation therapy treatment. Finally, 
we expect regions with higher densities of radiation oncologists to be associated with 
lower prostate cancer mortality rates.   
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Methods 
Data Sources 
 This study utilized three publically available data sources. The Area Resource File 
provided regional demographic, population, and physician distribution data.33,34 The 
Surveillance Epidemiology End Results Public-Use Dataset provided clinical, 
demographic, and treatment data for patients diagnosed with prostate cancer. 34 Finally, 
the State Cancer Profiles Dataset provided regional prostate cancer specific mortality 
data.35 
The Area Resource File 
Using the 1995 and 2007 editions of the Area Resource File (ARF), we obtained 
demographic, population, and physician distribution data.33 Published by the Health 
Resources and Services Administration of the US Department of Health and Human 
Services, the ARF is a collection of data from over 50 sources, including the American 
Medical Association, American Hospitalization Association, US Census, and National 
Center for US Health Statistics. The ARF aggregates information concerning the 
healthcare professionals, healthcare facilities, and population for each county in the 
United States. Specifically, the ARF includes the number of specialists within each 
county based on data from the American Medical Association (AMA) Physician 
Masterfile.   
The Surveillance Epidemiology End Results Public-Use Dataset 
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 We obtained patient linked prostate cancer treatment choice data from the 
Surveillance Epidemiology End Results (SEER) Public-Use Dataset. The SEER Public-
Use Dataset provided demographic staging, pathologic findings, extent of surgery, and 
receipt of radiation therapy for patients treated with prostate cancer for the years 2004 
through 2007. Originally established in 1973 by the National Cancer Institute (NCI) the 
SEER Public-Use Dataset is an aggregate of population-based cancer registries across the 
United States. The SEER Public-Use Dataset comprises approximately 26% of the United 
States. The following state and individual population-based registries were included our 
analysis: Alaska Native Tumor Registry, Arizona Indians, Cherokee Nation, Connecticut, 
Detroit, Georgia Center for Cancer Statistics, Atlanta, Greater Georgia, Rural Georgia, 
Greater Bay Area Cancer Registry, San Francisco-Oakland, San Jose-Monterey, Greater 
California, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, 
Seattle-Puget Sound, Utah.34,36  
The State Cancer Profiles Dataset 
County level prostate cancer specific mortality and incidence data was obtained 
from the State Cancer Profiles Dataset. The State Cancer Profiles Dataset is a merged 
dataset from the NCI SEER program, National Program for Cancer Registries (NPCR), 
and United States Center for Disease Control and Prevention’s National Vital Statistics 
System.35 Prostate cancer specific mortality and incidence data were reported as age-
adjusted average rates per 100,000 people from the years 2003 to 2007. Cancer 
incidences and mortalities were assigned to counties based on patient residence at the 
time of diagnosis and death, respectively. 
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Geographic Units of Analysis 
National Cancer Institute Health Service Areas 
When evaluating trends in the geographic distribution of the radiation oncology 
workforce and the influence of geographic variations on prostate cancer treatment choice 
the geographic units of analysis were the 950 Health Service Areas (HSAs) within the 
United States as defined by the National Cancer Institute. HSAs are defined as a single 
county or group of contiguous counties that remain self-contained with respect to hospital 
care.16 HSAs were chosen as the unit of analysis because they best represent geographic 
access to healthcare within a region. County level data from the ARF was aggregated to 
HSAs using simple summation for physician and population variables and population 
weighted sums descriptive variables. Patients within the SEER Public-Use Dataset were 
assigned HSAs based on county-specific FIPS codes assigned to the patient based on 
residence. The data from the SEER Public-Use Dataset contained data for patients 
located in 170 HSAs comprising approximately 17.9% of the United States.  
United States Counties 
 When evaluating the association between geographic variations in the radiation 
oncology workforce and regional prostate cancer specific mortality the geographic units 
of analysis were the 3,141 counties in the United States as defined by the 2000 Census. 
Counties were specifically chosen for analysis of regional prostate cancer specific 
mortality because the State Cancer Profiles dataset that could not be accurately 
aggregated to HSAs. Similar to previous studies investigating the impact of physician 
density on cancer-related mortality, rural counties were excluded from the analysis 
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because only 0.4% of the 669 rural counties in the United States possessed radiation 
oncologists and many of them lacked complete mortality data.6,8 Following exclusion of 
rural counties, 2,472 non-rural counties comprising approximately 78.7% of the United 
States possessed complete mortality data and were available for analysis. Counties were 
classified as rural based on 2003 Department of Agriculture Rural/Urban Continuum 
Codes.  
Trends in the Geographic Distribution of the Radiation Oncology Workforce  
To evaluate the geographic distribution of radiation oncologists across the United 
States the primary outcome was the ratio of radiation oncologists to population aged 65 
or older (ROR). The physician to population ratio remains a frequently used measure of 
physician distribution within a region. 6,37 The elderly were chosen as the population of 
interest because they represent a group that has the highest prevalence of cancer and 
represent a demographic which utilizes a significant portion of healthcare services in the 
United States. 18,38 In addition, elderly patients may be less mobile than younger patients, 
and may be more hesitant to travel long distances for their care meaning geographic 
proximity is of utmost importance. The ROR of each HSA was calculated as the number 
of radiation oncologists per 100,000 people aged 65 or older. RORs for each HSA were 
generated for the years 1995 and 2007. To compare the distribution of radiation 
oncologists to other physician specialties, equivalent ratios were calculated for the 
primary care physician (PCPR) and total physician (MDR) workforces. PCPs were 
defined as physicians in general practice, family practice, or general internal medicine. 
Population aged 65 or older estimates and physician workforce estimates were obtained 
from the ARF. 
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To evaluate changes in the distribution of the workforce, mean RORs were 
calculated for 1995 and 2007 and compared with equivalent changes in PCPR and MDR. 
To assess the current distribution of radiation oncologists, each HSA was ranked based 
on ROR and compared to equivalent rankings of PCPRs and MDRs.  In an effort to 
visually compare the distribution of radiation oncologists between different HSAs and 
trends in their distribution, ROR values were mapped to corresponding HSAs. 
Lorenz Curves and Gini Coefficients 
Traditionally used to assess distribution of wealth, Gini coefficients and Lorenz 
curves have recently been used to evaluate physician distribution. 37,39,40 The Lorenz 
curve was constructed by graphing the cumulative percentage of radiation oncologists as 
ranked by RORs versus the cumulative percentage of the population age 65 or older. A 
45° line representing a perfectly even distribution was drawn from the origin to the 
maximum point of the Lorenz curve. The Gini coefficient was calculated by dividing the 
area between the Lorenz curve and the 45° line by the total area under the 45° line. The 
Gini coefficient ranges in value from 0 (complete equity) to 1 (complete inequity) and 
serves as a quantitative way to describe relative ‘evenness’ of physician distribution. 
Because Gini coefficients possess a linear relationship, changes in value can be used to 
evaluate changes in the evenness of physician distributions over time. Lorenz curves and 
Gini coefficients were generated to examine the radiation oncologist distribution among 
all HSAs between 1995 and 2007.  Subgroup analysis was performed to compare the 
evenness of radiation oncologist distribution, specifically in less populated HSAs, using 
population quartiles. To assess the uniqueness of the radiation oncologist distribution 
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compared to all other physicians and PCPs, Lorenz curves and Gini coefficients were also 
calculated for all physicians and PCPs between 1995 and 2007.  
Negative Binomial Regression Analysis 
To evaluate population characteristics potentially associated with the current 
geographic distribution of radiation oncologists, regression analysis was used.  After 
assessing distribution, mean, and variance of HSA-level ROR, zero-inflated negative 
binomial regression was chosen. The dependent variable was ROR for the year 2007. The 
independent variables included county level population race, income, education, and 
unemployment rate obtained from the ARF that were aggregated to HSA level using 
weighted sums. Population race was defined as percentage white population within each 
HSA from the 2000 Census. Population income was defined as the median household 
income according to the 2007 Census update. Population education was defined as 
percentage population age 25 or older with at least a high school education according to 
the 2000 Census. Finally, unemployment rates for each HSA were from the 2007 Bureau 
of Labor Statistics estimates. Independent multivariate regression models were built 
using backwards-stepwise selection with a univariate p<.15 for inclusion into the model. 
A Vuong test was used to assess the appropriateness of the model. Statistical significance 
was determined at p<.05.  
Radiation Oncologist Distribution and Prostate Cancer Management 
To evaluate whether variations in the distribution of radiation oncologists was 
associated patient decisions to undergo treatment for prostate cancer, prostate cancer 
treatment and patient data were obtained from the SEER Public-Use dataset and merged 
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with physician workforce and socioeconomic data from the ARF for the years 2004 
through 2007.  Each prostate cancer patient within the registry was assigned physician 
workforce densities and socioeconomic data based on their HSA of residence. In addition 
to radiation oncologist densities, primary care physician and urologist densities were also 
obtained because of their previously described influence on prostate cancer screening and 
treatment outcomes.6,31 Densities were reported per 100,000 residents using 4-year (2004-
2007) population averages based on US Census estimates. To examine if incremental 
changes in radiation oncologist density accompany changes in the management of 
prostate cancer, radiation oncologist densities were categorized (0, 0.1 to 1.0, 1.1 to 2, 2.1 
to 3.0, >3.0 per 100,000 people).  Socioeconomic variables of interest included 
population income, unemployment rates, and population education. The socioeconomic 
data were obtained from the ARF and aggregated as stated above.  
Because appropriate prostate cancer intervention varies based on aggressiveness 
of disease patients were classified into low, intermediate and high-risk categories based 
on NCCN criteria.41 Patients were defined as ‘low-risk’ if their prostate cancer was 
Gleason 6, possessed a PSA < 10.0, and staged T1cN0M0. Patients were defined as 
‘high-risk’ if their prostate cancer was Gleason 8-10, presented with a PSA > 20.0, or 
staged T3N0M0. Individual patient characteristics were obtained from the SEER-Public 
Use data and included in the analysis. Patient characteristics of interest were patient race, 
age, and marital status. Treatment choice data obtained from the SEER Public-Use 
Dataset and were defined as ‘observation’ or ‘attempted curative therapy’. Attempted 
curative therapy consisted of a radical prostatectomy, radiation therapy (External-Beam 
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Radiation Therapy and brachytherapy) or combination surgical and radiation therapy 
treatment.  
Logistic Regression Analysis 
A primary logistic regression model was built for the entire cohort to evaluate the 
association between radiation oncologist density and observation of prostate cancer.  For 
patients who attempted curative therapy, two additional logistic models were built to test 
the association between radiation oncologist densities and the type of curative therapy 
chosen. The primary outcome variables for these additional models were receipt of a 
radical prostatectomy and receipt of radiation therapy respectively. Independent 
multivariate regression models using the above covariates were built using backwards-
stepwise selection with a univariate p<.15 for inclusion into the multivariate model.  
Statistical significance was determined at p<.05. 
Radiation Oncologist Distribution and Prostate Cancer Mortality 
To evaluate whether regional variations in the radiation oncologist workforce 
impacted prostate cancer outcomes, physician workforce and socioeconomic data from 
the ARF was combined with county-level prostate cancer specific mortality data from the 
State Cancer Profiles Dataset for the years 2003 through 2007.  Socioeconomic variables 
of interest included population income, unemployment rates, and population education as 
defined above. To account for geographic variations patient populations, percent 
population Caucasian, percent population aged 65 or older based on the Census County 
File were also included in the analysis.  
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In addition to radiation oncologist density, urologist and primary care physician 
densities were analyzed. In an effort to assess if reductions in prostate cancer mortality 
were related to non-specific specialists, a non-oncology specialty, Allergy-Immunology, 
was chosen as a control variable to test whether changes in cancer mortality were more 
specifically attributed to radiation oncologist density.  Allergists-Immunologists were 
chosen a priori as an ideal comparison specialist because they have no known 
associations to prostate cancer management and possess a workforce size and geographic 
distribution similar to that of radiation oncology. Physician densities were calculated as 
five-year means (2003 to 2007) of physicians per 100,000 people using annual Census 
county population estimates. 
Prostate cancer specific mortality data from the State Cancer Profiles data were 
reported as county-level age-adjusted average rates per 100,000 people from the years 
2003 to 2007. In an effort to better examine if incremental changes in radiation 
oncologist density accompany changes in prostate cancer mortality, radiation oncologist 
densities were categorized (0, 0.1 to 1.0, 1.1 to 2, 2.1 to 4.0, >4.0 per 100,000 people). To 
account for potential geographic variations in prostate cancer screening, prostate cancer 
incidence among counties in the United States was also included in the model. Cancer 
incidences and mortalities were calculated for each county based on each a patient’s 
residence at the time of diagnosis and death, respectively.  
Linear Regression Analysis 
 A linear regression model was built with prostate cancer mortality per 100,000 
people as the primary outcome variable. Univariate associations between physician 
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workforce, health system, and socioeconomic predictor variables and cancer mortality 
were calculated using t tests for categorical variables and linear regression for continuous 
variables. The multivariate model were built using backward stepwise selection with a 
univariate p<0.15 for inclusion into the model. Allergist-Immunologist density was 
manually inserted into the final model to control for changes in cancer mortality that 
could potentially be attributed to a high overall specialist density. Statistically 
insignificant Allergist-Immunologist density in the final model would suggest changes in 
cancer mortality were likely unattributed to high overall specialist density. Statistical 
significance for the final models was determined at p<0.05. Variance inflation factors 
were used to control for excessive collinearity amongst variables. Percent changes in 
mortality were calculated for each density category using the cancer mortality of a 
reference group. The reference group in all three models was a county with no radiation 
oncologists, urologists or allergists. To evaluate incremental benefits derived from 
increasing radiation oncologist density beyond the reference group, linear combination 
estimates were calculated comparing radiation oncologists among different density 
categories.  
Statistical analysis was conducted using SAS Version 9.2  (SAS, Cary, NC) and 
Stata Version 9.2 (Stata, College Station, TX). Mapping of data was done using the 
geographical information system ArcGIS Version 9.2 (Environmental Systems Research 
Institute, Inc., Redlands, CA). Transformation of data between geographic units was done 
using a combination of ArcGIS Version 9.2 (Environmental Systems Research Institute, 
Inc., Redlands, CA), SAS Version 9.2  (SAS, Cary, NC) and Stata Version 9.2 (Stata, 
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College Station, TX). All data transformation, statistical analysis, and map creation was 
completed independently by Sanjay Aneja, BS and overseen by James B. Yu, MD.  
Results 
Trends in the Geographic Distribution of the Radiation Oncology Workforce  
In the twelve-year period of our study, the radiation oncology workforce grew 
approximately 24%, from 3,515 radiation oncologists in 1995 to 4,378 in 2007. Over the 
same time period, the PCP workforce grew approximately 31%, from 213,619 physicians 
to 278,728. Similarly, the overall physician workforce grew 29%, from 617,362 
physicians to 794,184. The mean ROR increased by slightly more than one radiation 
oncologist per 100,000 people. (Table 1) In contrast, mean PCPR and MDR increased by 
85 physicians per 100,000 people and 145 physicians per 100,000 people, respectively. 
Increases in the mean ROR, although modest, suggest a growth in the radiation oncology 
workforce that outpaced the growth of the elderly population.  
Table 1: Mean Physician to Population Aged 65 or Older Ratio: 1995 and 2007 
 
 
The distribution of radiation oncologists was significantly more skewed than 
PCPs and MDs. In the year 2007, approximately 44% of HSAs within the United States 
  1995 2007 % Change 
Radiation Oncologists per 100,000 5.08 6.16 21.26 
PCP per 100,000 521.67 606.50 16.26 
MD per 100,000 1056.44 1201.35 13.72 
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lacked a radiation oncologist. Comparatively, approximately .74% of HSAs lacked a PCP 
and .63% lacked a physician of any kind. Moreover, approximately 75% of HSAs had 
two or fewer radiation oncologists per 100,000 people aged 65 or older. Additionally, 
there existed consistent geographic maldistribution of radiation oncologists from 1995 to 
2007. (Figure 1) HSAs within the Northeast, California, and Florida exhibited high 
RORs in both 1995 and 2007, whereas rural HSAs within the Midwest generally 
exhibited lower RORs in 1995 and 2007 relative to the rest of the country. (Figure 2)   
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Figure 2: Ratios of Radiation Oncologists to Population Aged 65 or Older Among Health 
Service Areas: 1995, 2007 
 
 
Equitable Distribution of the Radiation Oncologist Workforce 
Gini coefficient calculations confirmed the maldistribution of the radiation 
oncology workforce. Radiation oncologists were less evenly distributed than both PCPs 
and MDs in both 1995 and 2007. (Table 2) However, the Gini coefficients of all three 
groups exhibited a percentage decrease, indicating an improvement in distribution 
towards equity. Radiation oncologists exhibited the largest change (-10.93%), followed 
by PCPs (-4.85%) and finally MDs (-2.34%).  Analysis of Gini coefficients within 
population quartiles highlighted the uneven distribution of radiation oncologists in non-
metropolitan areas. Specifically we found that, unlike PCPs and MDs who possessed 
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relatively similar Gini coefficients among different population quartiles, the Gini 
coefficient of radiation oncologists in the lowest population quartile was an 
inequitable .951, compared to .251 in the highest population quartile. (Table 3) The 
difference between Gini coefficients among population quartiles suggests the geographic 
maldistribution of radiation oncologists stems primarily from inequity in less populated 
non-metropolitan HSAs.  
Table 2: Trends Gini Coefficients Among Different Physicians, 1995-2007 
 
 
Table 3: Gini Coefficients Among Population Quartiles, 2007 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Radiation Oncologists 0.951 0.675 0.402 0.251 
PCP 0.268 0.233 0.232 0.169 
MD 0.333 0.258 0.265 0.236 
 
Factors Associated with Radiation Oncologist Distribution 
Regression analysis found an association between radiation oncologist 
distribution and population characteristics. Univariate Zero Inflated Negative Binomial 
Regression showed that increased ROR in 2007 was associated with HSAs with lower 
unemployment rates (p<.001), higher household incomes (p<.001), and higher education 
  1995 2007 Change % Change 
Radiation Oncologists 0.366 0.326 -0.040 -10.93 
PCP 0.206 0.196 -0.010 -4.85 
MD 0.299 0.292 -0.007 -2.34 
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rates (p=.001). (Table 4) Surprisingly, decreased ROR in 2007 was associated with 
HSAs that had higher percent white population (p=.022). Multivariate analysis confirmed 
the association between increased ROR and lower unemployment rates (p<.001), higher 
household incomes (p<.001), and increased minority population (p=.010). Higher 
education rates proved to be insignificant in the multivariate model (p= .461). Because 
the association between minority population and ROR was unexpected, a separate model 
using percent African American population was built to confirm the association with 
minority groups. The confirmatory model yielded similar results (p<.001). 
Table 4: Socioeconomic Factors Associated with ROR: 2007 





Ratio p 95% CI 
Incidence 
Rate 
Ratio p 95% CI 
Percent White 
Population .995 .022 .992 .999 .995 .010 .991 .978 
Unemployment 
Rate .889 <.001 .858 .921 .906 <.001 .872 .891 
Percent High 
School 




$10K) 1.01 <.001 1.00 1.02 1.01 <.001 1.00 1.02 
 
Radiation Oncologist Distribution and Prostate Cancer Management 
We isolated 108,613 prostate cancer patients from the SEER Public-Use Dataset. 
16,969 (15.6%) patients opted for active surveillance of their prostate cancer. (Table 5) 
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47,484 (43.7%) of patients underwent some form of radiation therapy and 45,367 
(41,8%) underwent radical prostatectomy. Single (p<.001), older (p<.001), African 
American (p<.001) patients with low-risk disease (p<.001) residing in HSAs with fewer 
radiation oncologists (p=.001-.041), fewer urologists (p<.001),  and more primary care 
physicians (p<.001) were most likely to pursue active surveillance. (Table 6) Of the 
91,643 (84.38%) of patients who underwent some form of curative treatment, older, 
single (p<.001), African American patients (p<.001) with low-risk disease (p<.001) 
residing in HSAs with more radiation oncologists (p=.007-.001) and primary care 
physicians (p<.001) were more likely to some form of receive radiation therapy. (Table 
7)  Conversely, married (p<.001), white (p<.001), younger (p<.001) patients with higher 
risk disease (p<.001) living in HSAs with fewer radiation oncologists (p=.006-.001), 
more urologists (p<.001) and fewer primary care physicians (p<.001) were likely to 
receive a radical prostatectomy. Incremental increases in radiation oncologist density 
were associated with commiserate decreases likelihood of surgical treatment and 
observation.  
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Table 5: Prostate Cancer Patients: SEER Public-Use Dataset 2004-2007 
 
N % 
Total 108,613 100.0% 
Treatment Choice 
  Observation 16,969 15.6% 
Radiation Therapy 47,484 43.7% 
Radical Prostatectomy 45,367 41.8% 
Race 
  White 88,898 81.8% 
African American 13,586 12.5% 
Other 6,058 5.6% 
Married 85,106 78.4% 
NCCN Risk Group 
  Low Risk 30,782 28.3% 
Intermediate Risk 61,863 57.0% 
High Risk 15,967 14.7% 
 
Median 
 Age 65 
 Radiation Oncologists 
Per 100,000 1.44 
 Urologists Per 100,000 3.29 
 PCP Per 100,000 66.69 
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Table 6: Predictors of Active Surveillance of Prostate Cancer: 2004 to 2007 
  Observation  
  
Odds 
Ratio P 95% CI 
Radiation Oncologists 
per 100,000         
>0-1.0 v 0 .895 .030 .810 .989 
>1.0-2.0 v 0 .856 .001 .847 .864 
>2.0-3.0 v 0 .845 .002 .758 .942 
>3.0 v 0 .851 .041 .730 .994 
Urologists per 
100,000  .920 <.001 .902 .939 
PCPs per 100,000 1.005 <.001 1.004 1.007 
Age 1.097 <.001 1.094 1.099 
Race         
African American v 
White 1.621 <.001 1.540 1.706 
Other v White .878 .001 .814 .947 
Married 0.632 <.001 0.608 0.658 
NCCN Risk Group         
Intermediate v Low 0.607 <.001 0.584 0.632 
High v Low 0.765 <.001 0.726 0.806 
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Table 7: Predictors of Prostate Cancer Treatment Interventions: 2004 to 2007 
  Radical Prostatectomy Radiation Therapy  
  
Odds 
Ratio P 95% CI 
Odds 
Ratio P 95% CI 
Radiation 
Oncologists 
per 100,000                 
>0-1.0 v 0 .886 .006 0.813 .967 1.125 .007 1.033 1.226 
>1.0-2.0 v 0 .832 <.001 0.825 .839 1.194 .001 1.062 1.326 
>2.0-3.0 v 0 .814 <.001 0.741 .894 1.261 <.001 1.149 1.383 
>3.0 v 0 .729 <.001 0.638 .833 1.370 <.001 1.201 1.563 
Urologists 
per 100,000  1.129 <.001 1.084 1.173 0.985 .071 .968 1.001 
PCPs per 
100,000 .995 <.001 0.994 .997 1.005 <.001 1.004 1.006 
Age .877 <.001 0.875 .879 1.125 <.001 1.123 1.128 
Race                 
African 
American v 
White .545 <.001 .520 .571 1.779 <.001 1.698 1.863 
Other v 
White .912 .006 .854 .974 1.154 <.001 1.081 1.232 
Married 1.517 <.001 1.461 1.574 0.690 <.001 0.665 0.716 
NCCN Risk 
Group                 
Intermediate 
v Low 2.010 <.001 1.943 2.080 0.534 <.001 0.516 0.552 
High v Low 1.388 <.001 1.320 1.458 1.009 0.711 0.961 1.061 
 
Radiation Oncologist Distribution and Prostate Cancer Mortality 
Similar to HSAs the radiation oncologist was heterogeneously distributed among 
counties in the United States, with 1,616 (65.3%) counties lacking the presence of any 
radiation oncologists. (Figure 3) Of the 2,472 counties studied 1205 (48.7%) were 
without the presence of both a radiation oncologist and urologist. The mean radiation 
oncology and urologist densities among counties were .65 and 2.00 per 100,000 
respectively. The baseline prostate cancer mortality in a county without the presence of a 
radiation oncologist, urologist, or allergist was 38.68 deaths per 100,000 people (95% CI 
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33.94-43.42). The presence of a radiation oncologist was associated with a statistically 
significant reduction in prostate cancer mortality, despite adjusting for variations in 
urologist and allergist/immunologist density, as well as socioeconomic, demographic and 
health system characteristics (Table 8).  Compared to counties without radiation 
oncologists, having >0-1, 1-2, or 2-4 radiation oncologists per 100,000 people 
significantly reduced prostate cancer specific mortality by -3.65% (p=0.031), 5.74% 
(p<0.001), and 1.48% (p=0.045), respectively.  The prostate cancer specific mortality of 
patients residing in a county with 4 or more radiation oncologists per 100,000 people was 
not significantly different from counties where there were no radiation oncologists 
(p=.769). The confidence intervals of this group were wide, given the small number of 
counties with 4 or more radiation oncologists per 100,000 residents. (Figure 4) Linear 
combination estimates found increasing radiation oncologist density beyond 1.0 per 
100,000 provided no statistically significant incremental reductions in prostate cancer 
mortality compared to having 0.1-1.0 radiation oncologists per 100,000. (Table 9) 
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Figure 4: Reduction in Prostate Cancer Mortality for a Given Radiation Oncologist Density 






























Radiation Oncologist Density Categories (per 100,000) 
   0             >0-1.0       >1.0-2.0       >2.0-4.0       >4.0 
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Table 8: Predictors of County Level Prostate Cancer Mortality: 2003-2007 
 
% Change in 
Prostate Cancer 
Mortality P 95% CI 
Radiation Oncologists per 100,000 
People 
    >0-1.0 v 0 -3.65 .031 -5.54 -1.76 
>1.0-2.0 v 0 -5.74 <.001 -7.87 -3.61 
>2.0-4.0 v 0 -1.48 .045 -2.73 -0.23 
>4.0 v 0 -1.09 .769 -3.69 1.51 
Urologists per 100,000 People -12.63 <.001 -16.43 -6.60 
Allergist Immunologists per 
100,000 People -0.59 .340 -1.80 0.62 
Percent Population Aged 65 or 
Older 1.23 .001 0.51 1.94 
Median Household Income (in 
$10,000) -2.97 <.001 -4.17 -1.76 
Percent Population with High 
school Education -0.17 <.001 -0.01 -5.14 
Percent White Population -0.39 <.001 -0.47 -0.31 







Reference Group: Prostate Cancer 
Mortality in a county with no 




*Note: Primary care physician density, and unemployment rate either did not meet univariate 
inclusion criteria or were not statistically significant in multivariate model. 
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Table 9: Incremental Benefit of Increasing Radiation Oncologist Density on Prostate 
Cancer Mortality 
 
Prostate Cancer Mortality 
Radiation Oncology Density 
Categories % Change in Mortality P OR 
1.1-2.0 v 0.1-1.0 -2.1 0.221 0.45 
2.1-4.0 v 1.1-2.0 4.3 .190 1.81 
>4.0 v 2.1-4.0 0.4 .912 1.16 
 
Consistent with previous studies, increasing density of urologists also was 
associated with a reduction in prostate cancer mortality (p<.001).  Allergist/Immunologist 
density was not related to prostate cancer mortality (p=0.340). Residing in a more 
affluent county with a younger and more educated population was correlated with 
reduced prostate cancer mortality (Table 8). Moreover, racial makeup of counties was 
found to be associated with variations in prostate cancer mortality. Counties with higher 
percentages of Caucasians were associated with reduction in prostate cancer mortality 
(p<.001). Primary care physician density and county unemployment rate were both not 
significant in the multivariate model.  
Discussion 
This study serves as one of the first comprehensive geographic analyses of the 
radiation oncology workforce. We found that despite a modest growth in the radiation 
oncology workforce over the 12 years there remained a persistent geographic 
maldistribution of radiation oncologists across the United States. The uneven distribution 
of radiation oncologists is associated with socioeconomic characteristics and most 
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profoundly seen in rural regions. Moreover, the growth in the radiation oncology 
workforce over the 12 years did not match the growth of the overall physician workforce 
and primary care workforces during the same period of time. Furthermore, geographic 
variations in the workforce were associated with regional variations in the management 
of prostate cancer. Finally and arguably most concerning, we found an association 
between geographic variations in the radiation oncologist workforce and county-level 
prostate cancer outcomes with regions lacking radiation oncologists having increased 
prostate cancer specific mortality rates even when adjusted for variations in prostate 
cancer incidence. Our study suggests that the physician workforce problem should not 
merely focus on physician numbers but also the geographic distribution of physicians.   
The growth in the radiation oncology workforce was modest compared to the 
overall growth in the physician workforce. The radiation oncology workforce grew 5% 
less than the overall physician workforce and 9% less than the primary care workforce. In 
a 12-year period, the mean ROR increased by slightly more than one radiation oncologist 
per 100,000 people aged 65 or older compared to larger increases in the PCPR and MDRs. 
The modest growth in the radiation oncology workforce is most likely due to increasing 
residency positions for radiation oncology.42-44 
Despite growth in the workforce, there was persistent geographic variation in the 
distribution of radiation oncologists in 1995 and 2007. Mapping of the RORs for 1995 
and 2007 showed large geographic segments of the elderly population having little or no 
access to radiation therapy services, specifically in non-metropolitan areas. In 2007, an 
alarming 44% of HSAs in the United States lacked radiation oncologists. This translated 
to 3,137,580 people aged 65 or older without access to radiation therapy in their HSA. 
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Comparatively, Gini analysis showed radiation oncologists were less evenly distributed 
than both PCPs and the overall physician workforce. Our finding that PCPs were the 
most evenly distributed replicates findings from previous studies and suggests that recent 
policy initiatives to increase geographic access to primary care have been successful. 37,45 
More interestingly, the main driver in the uneven geographic distribution of radiation 
oncologists was an inequitable distribution in less populated non-metropolitan HSAs.  
The lack of access to radiation oncologists in less populated non-metropolitan areas is 
perhaps due to the large capital investment required to obtain the equipment and 
resources necessary to establish a radiation oncology practice. These impediments are 
increased in rural areas where patient population levels are potentially less. Conversely, 
large pockets of radiation oncologists were centered in metropolitan areas with large 
academic centers. This finding corroborates previous findings from the ASTRO 
workforce committee that groups of ten or more radiation oncologists are more likely to 
be in academic centers. 17 The clustering of radiation oncologists in academic centers is 
perhaps due to recent increases in academic radiation oncology due to an influx of 
physician scientists in radiation oncology residency programs, or due to the attractiveness 
of technological resources available at academic centers.46 
Our analysis found that access to radiation oncology services was allocated along 
socioeconomic and racial characteristics and provides information for policy makers on 
potential factors that affect radiation oncologist distribution, and could be used for future 
legislation aimed at physician recruitment to underserved areas.  Although Hayanga et al 
found access to radiation oncologists to be associated with decreased minority population 
on the county level, our analysis found a positive association between minority 
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population and ROR within HSAs.47 The reason for this difference is partly because our 
negative binomial regression model more accurately predicted radiation oncologist 
density given the distribution compared to the linear regression used in their analysis. 
Also, our geographic units of analysis were HSAs, which better predict patterns of 
healthcare usage compared to counties. Additionally, unlike previous analysis, our ROR 
outcome variable accounts for the variation in population density across the United States 
and is more accurate than gross physician totals. Moreover, unlike previous analyses, our 
analysis excluded counties located in US territories such as Guam, Puerto Rico and the 
US Virgin Islands that generally have disproportionate minority populations and skewed 
access to specialists. Our findings suggest that, although racial disparities in cancer 
outcomes have been well documented, minority populations generally reside within 
HSAs in close proximity to radiation oncologists. 48 
Our findings highlight the problem of physician recruitment to rural areas. 
Recently, rural physician recruitment efforts have faced obstacles because of the 
technological gap that exists in rural settings. This problem is evermore important in a 
highly technical field like radiation oncology and has translated to patient dissatisfaction 
as physician retention rates in rural areas have decreased. 46 Traditional policymakers 
have theorized that market forces and rural incentives would decrease geographic 
disparities as the workforce increases. 49 However, we found little or no decrease in 
geographic variability of radiation oncologists to accompany a growth in the workforce. 
The significant non-physician personnel needed to operate radiation therapy facilities 
could also be a factor in the geographic maldistribution of radiation oncologists. The 
workforce shortages of radiation oncologists exacerbated with corresponding workforce 
	   38	  
shortages in non-physician personnel, such as dosimetrists and medical physicists 50, 
perhaps make it difficult provide cost-effective quality radiation therapy in rural areas in 
the United States. Recently, studies have suggested the solution to geographic 
maldistribution is not increased recruitment to rural areas, but rather, technical 
innovations that increase the efficiency of healthcare for rural populations. 51-54 An 
example of a treatment innovation, specifically in radiation therapy, is hypofractionated 
treatment, as performed for breast radiotherapy in Canada (the so-called, “Canadian 
fractionation”) where geographic distance between radiation oncology centers is even 
more severe than the United States.  
We explored the implications of a geographically maldistributed workforce on 
management of prostate cancer. Patients in HSAs without radiation oncologists were 
more likely to choose active surveillance even when possessing high-risk disease. 
Additionally, patients in HSAs lacking the presence of radiation oncologists were more 
likely to undergo radical prostatectomy as primary treatment. Our findings corroborate 
previous evidence that found an association with patient visits to urologists and radiation 
oncologists and patient prostate cancer treatment choice.31,55 Our study highlights the 
need for multidisciplinary care in order for patients to make informed decisions regarding 
prostate cancer treatment. Additionally, recent evidence that suggests multidisciplinary 
care alters treatment patterns for patients with localized prostate cancer.55 Interestingly, 
we found primary care physician density to be associated with increased active 
surveillance of prostate cancer. This is perhaps because patients who have access to 
primary care physicians are more likely to successfully monitor low-risk prostate cancer 
through active surveillance. Lastly, we confirmed previous evidence suggesting marital 
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status, age, and patient race are related to patient decisions to pursue active surveillance 
of prostate cancer in lieu of curative therapy. 
 The geographic distribution of the radiation oncology workforce is associated 
with differences in prostate cancer mortality. The presence of a single radiation 
oncologist in a county was associated with a statistically significant reduction in prostate 
cancer specific mortality.  The improvement in prostate cancer mortality persisted even 
when adjusting for regional prostate cancer incidence, other physician densities, and 
socioeconomic factors. Interestingly, incremental increases of radiation oncologists in a 
county did not yield incremental benefits in outcomes, suggesting a ‘plateau effect’ when 
a region becomes saturated with radiation oncologists. These results corroborate with 
similar studies that found diminishing returns with increases in physician supply.15,56 
 Radiation therapy is one of the most common treatments for prostate cancer.  
Although our study does not directly test the clinical implications of radiation therapy 
and prostate treatment, it does highlight a potential association between the availability of 
radiation therapy and improved prostate cancer outcomes. Radiation oncologist density 
may be a surrogate for specialized oncology care, specifically the presence of large 
cancer centers with multidisciplinary tumor boards and a variety of non-radiation prostate 
cancer specialists. Although improved outcomes cannot definitively be attributed to the 
presence of a radiation oncologist, our findings of improved prostate cancer mortality, 
despite adjustment for urologist and allergist/immunologist density, speak to the 
robustness of the specific association between radiation oncologist density and prostate 
cancer mortality.  Another possible explanation for our findings is that radiation 
oncologists are a proxy for other general oncology indicators that could not be fully 
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adjusted for in our multivariate model. For example, the presence of a large cancer center 
with access to more advanced treatment technologies and multidisciplinary tumor boards 
to better coordinate prostate cancer care between urologists and radiation oncologists. 
Our study also highlighted previously cited racial disparities in prostate cancer outcomes. 
Counties with larger proportions of Caucasians were associated with increased prostate 
cancer mortality reduction. This is likely because minorities have been shown to present 
with more advanced prostate cancer which carries a worse prognosis.57 Furthermore, 
when adjusting for other factors known to influence cancer outcomes, such as 
socioeconomic factors (median household income, population education level) the 
presence of radiation oncologists was associated with prostate cancer mortality, 
highlighting the relative uniqueness of radiation oncologist to prostate cancer 
management. 
Our, analysis found increasing urologist density to have a more profound effect 
on prostate cancer specific mortality compared to radiation oncologist density. The 
reasons for this are likely multifactorial. Firstly, because of greater number of urologists 
compared to radiation oncologists the impact of urologists on prostate cancer mortality 
maybe more easily seen. Secondly, because urologists are involved in the screening and 
diagnosis of prostate cancer in addition to surgical treatment, increased density of 
urologists may be associated with increased likelihood to be diagnosed at an earlier stage 
with a more favorable prognosis. Conversely, radiation oncologists serve only a curative 
role in prostate cancer treatment and require another clinical provider, typically a 
urologists or primary care physician, to refer a prostate cancer patient to them. In a 
counties with poor primary care and urologist presence radiation oncologists may be 
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faced the challenge of treating higher stage prostate cancers that were not screened and 
thusly diagnosed later. 
County-level analysis confirmed the previously described geographic 
maldistribution of radiation oncologists across health services areas. Large segments of 
the population live in counties without a radiation oncologist, and this in turn is 
associated with increased prostate cancer mortality. To complicate the problem, creating 
an equitable distribution of radiation oncology services remains difficult. Unlike many 
other medical specialties, radiation oncologists require significant equipment to provide 
treatment, making radiation therapy relatively insular to increasingly popular 
telemedicine initiatives. Additionally, the large investment required to start a radiation 
oncology practice may contribute to apprehension of radiation oncologists entering the 
field to establish a practice in an underserved area. 
The mechanism by which radiation oncologist density is related to prostate cancer 
mortality is difficult to pinpoint. Prior work has shown that radiation oncologist and 
urologist density was not predictive of whether patients receive any curative therapy. 
Rather, individual patient characteristics, such as marital status, are predictive of receipt 
curative treatment.58 However, our previous analysis suggests radiation oncologist and 
urologist density are predictive of whether patients choose radiation therapy or surgery as 
the treatment modality for prostate cancer.59 It is plausible that regional physician density 
is related to aspects of management about which patients are less informed, such as 
nuanced treatment modalities, but decisions related to larger questions of whether to 
receive curative treatment are ultimately personal ones. Furthermore, as geographic 
differences in prostate cancer mortality have mainly been attributed to differences in 
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disease stage related to time of diagnosis, an aspect of care with which radiation 
oncologists are not typically involved, the density of radiation oncologists may be of less 
utility.26  Perhaps it is the radiation oncologist’s role in providing truly multidisciplinary 
cancer care that most influences mortality.  Where previous investigators found an 
association between urologist density and prostate cancer mortality, we found a similar 
association for radiation oncologists, even when adjusting for the presence of urologists 
and variations in prostate cancer incidence.15  Therefore, our two studies in combination 
highlight the importance of multidisciplinary care in the management of patients with 
prostate cancer. 
 We found that the improvement in prostate cancer mortality did plateau beyond a 
radiation oncologist density of 1.0 per 100,000.  Reasons for this diminishing return may 
be because incremental improvement in prostate cancer mortality when comparing higher 
density categories was small relative to the large improvement in mortality from the 
addition of the first radiation oncologist to a county.  This plateau effect has been seen in 
similar studies of the physician, dermatology, neonatology workforces.5,8,56 Moreover, 
prostate cancer can be relatively indolent, in contrast to cervical cancer or head and neck 
cancers. Patients residing in areas with an oversubscribed radiation oncologist can 
potentially wait until prostate cancer treatment is available, perhaps mitigating the need 
for additional radiation oncologists to improve time between diagnosis and treatment. 
Limitations 
Our analysis has several limitations. First, the physician location data from the 
AMA masterfile does not capture physicians who have multiple practices in different 
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regions, and therefore it is possible that we have overestimated the geographic clustering 
of radiation oncologists.  However, though we believe that radiation oncologists are more 
likely to have multiple physician practice locations compared to primary care providers, 
we suspect that if radiation oncologists have multiple practices that they would be within 
the same HSA.  Unfortunately, this is unable to be confirmed by our data.  Second, the 
masterfile has been shown to underestimate physician shortages in rural areas. 60 Third, 
our study does not capture other barriers to care such as lack of health insurance and 
whether radiation oncology centers accept Medicaid payment for their services. Finally, 
our analysis cannot provide an optimal ROR because we did not relate geographic 
distribution to clinical outcomes.  Future analysis should focus on finding the radiation 
oncologist distribution that will optimize cancer outcomes.  We were unable to assess the 
impact of the availability of various radiation treatment modalities (EBRT, brachytherapy, 
SBRT), as no information was recorded as to the type of treatment available at each 
practice location. Another limitation of our study is the exclusion of rural counties when 
studying the association between radiation oncologist density and mortality within the 
United States. Unfortunately, the prostate cancer mortality data for some rural regions 
was unavailable. Nevertheless even if that data were available, the paucity and relatively 
maldistribution of radiation oncologists and urologists among rural counties would make 
it difficult to establish any reliable relationship between physician density and prostate 
cancer outcomes. What remains clear however is the variation in prostate cancer 
outcomes in resource poor and resource rich regions. Further studies focused on rural 
counties will be needed to better generalize the results of our analysis to rural areas. 
Additionally, patient-specific characteristics were unattainable using the merged State 
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Cancer Profiles data. Additionally, our analysis is subject to a theoretical lead-time bias 
associated with patients in underserved areas potentially being diagnosed later and with 
more advanced disease. This is due to a lack of available county-level stage and grade 
data. This limitation is present in studies of this nature6,8 and was somewhat mitigated by 
adjusting for geographic variations in prostate cancer incidence. Finally, given the 
relative slow growth of prostate cancer, current mortality is likely related to treatment 
options available upwards of 10-year prior. A multivariate model replacing current 
physician densities with physician densities from 1995 yielded similar results. This is 
likely because the geographic maldistribution of the radiation oncology and urology 
workforces have remained relatively unchanged within the last 15 years.15,16 The 
relationship between historical health system resources and long-term outcomes of a 
population in the years following is an interesting topic for future studies. Nevertheless, 
previously published studies of our similar nature6 our study is fundamentally an analysis 
of the current variations in healthcare systems across the United States. Using current 
physician densities as a proxy for current general oncology infrastructure and allows the 
study the relative robustness of current healthcare systems. Our analysis ultimately 
comments less on the well-established curative relationship between urologists and 
radiation oncologists for prostate cancer, rather more on the relationship between 
resource rich/poor regional healthcare systems and overall prostate cancer outcomes. In 
spite of these limitations, our analysis provides a first step in understanding the 
relationship between variations in the radiation oncologist workforce and prostate cancer 
mortality and serves as an impetus for further study of the effect of regional radiation 
oncologist therapy resources in the management of prostate cancer.   
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Conclusion 
 In this comprehensive geographic analysis of the physician workforce we 
highlighted a maldistribution of the radiation oncology workforce that has persisted for 
over a decade. The geographic variations are associated with tangible differences in the 
treatment of prostate cancer patients and regional prostate cancer mortality rates. Further 
policy discussions addressing the physician workforce must focus not only on gross 
numbers, but also geographic distribution.  Although it is difficult to quantify the ideal 
number of radiation oncologists needed in various regions in the United States, our study 
raises questions regarding whether certain regions are lacking adequate numbers of 
radiation oncologists.  Geographic aware policies are needed to optimize the physician 
workforce and provide quality oncology care throughout the United States.  
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